Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Rare Diseases

Melanoma

Skin Neoplasms

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Vaccines

Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.

Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.

Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.

In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.

Immunotherapeutic GSK2302025A, different formulations

GSK Clinical Trials

The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic \[ASCI\]) administered as a first line treatment in patients with unresectable and progressive metastatic cutaneous melanoma.

In this study, patients were to receive a maximum of 24 doses of recMAGE-A3 + AS15 according to four cycles over a period of four years. An active follow-phase (up to five years after registration into the study) was planned for all patients.

This protocol summary has been impacted by protocol amendment 3, so there will no longer be an active follow-up of patients after discontinuation or completion of the study treatment. The study will end approximately 30 days after the last dose will be administered.

In addition, no more biological samples will be collected for protocol research purposes. For each biological sample already collected in the scope of this study and not tested yet, testing will not be performed by default, except if a scientific rationale remains relevant.

Sampling for safety monitoring as per protocol will continue.

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma

IPD for this study will be made available via the Clinical Study Data Request site.

The dose-limiting toxicities (DLT) were defined as follows: •An Antigen-Specific Cancer Immunotherapeutic (ASCI) related or possibly ASCI related grade 3 or higher toxicity. Grade 3 myalgia, arthralgia, headache, fever, rigors/chills and fatigue (including lethargy, malaise and asthenia) persisting for 48 hours despite therapy. •An ASCI related or possibly ASCI related grade 2 or higher allergic reaction occurring within 24 hours following the ASCI administration. •An ASCI related or possibly ASCI related decrease in renal function, with a creatinine clearance lower than (\<) 40 milliliters per minute (mL/min). •An ASCI-related or possibly ASCI-related symptomatic and confirmed adrenal insufficiency. The grading used was defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 3 DLT = severe DLT. Related = DLT considered by investigator as possibly related to product administration.

A seronegative/seropositive patient for anti-PRAME antibodies was a patient with antibody concentration lower (\<)/ higher than or equal to (≥) cut-off level. Humoral immune response was defined as a) if baseline concentration \< cut-off level: post treatment concentration ≥ cut-off level, or b) if baseline concentration ≥ cut-off level: post treatment concentration at least twice the baseline value. Cut-off values for seropositivity (by enzyme-linked immunosorbent assay \[ELISA\]) were 12 ELISA Units per milliliter (EL.U/mL).

The best overall response is the best response recorded from the start of the treatment until disease progression (taking as reference for progressive disease the smallest measurements recorded since the treatment started). In general the patient's best response assignment depended on the achievement of both measurement and confirmation criteria. The best overall response includes the complete response (CR) defined as disappearance of all targeted/non-targeted lesions and partial response (PR) defined as at least 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD and persistence of one or more non-targeted lesion(s).

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE). Adverse Events were coded to the preferred term (PT) level by means of the Medical Dictionary for Regulatory Activities (MedDRA).

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE). SAEs were coded to the preferred term (PT) level by means of the Medical Dictionary for Regulatory Activities (MedDRA).

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Unknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[APTTP\] grading versus baseline parameter grading.

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[ALT/I\] and \[APH/I\] grading versus baseline parameter grading.

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[AN\], \[AST/I\] and \[CRE/I\] grading versus baseline parameter grading.

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[CRE/I\] and \[GGT/I\] grading versus baseline parameter grading.

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[Hgb/I\] and \[HYP\] grading versus baseline parameter grading.

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[LYMC/D\] and \[LYMC/I\] grading versus baseline parameter grading.

Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[NEUC/D\], \[PLA/D\] and \[WBC/D\] grading versus baseline parameter grading.

Cellular response was defined as: Geometric Mean Response (GMR) above the 2.68 cut-off value and at least a four-fold increase of PRAME- specific Cluster of Differentiation (CD) 4/8 T-cells. Considering that 2 studies failed to demonstrate clinical efficacy of recombinant protein based cancer vaccines, GSK decided in 2014 to stop the development and to stop recruitment in all the ongoing clinical studies. The decision was made to end the study (i.e., stopping patient enrollment, follow-ups, sample collection and analysis of samples for research purposes). Patients still on treatment at the time of the protocol amendment were offered to continue the administration of the study treatment until the last dose or until recurrence, whichever came first, or until the patient or the investigator decided to stop the study treatment. No further active protocol visit/contact was performed except for the concluding visit at Week 199, 30 days after the last treatment administration.

A seropositive patient was a patient whose anti-PRAME antibody concentration was greater than or equal to (≥) the assay cut-off value of 12 ELISA units per milliliter (EL.U/mL). A seronegative patient was defined as a patient whose pre-treatment antibody concentration was below (\<) the cut-off value. An anti-PRAME antibody responder was defined as: For a seronegative patient: a post-treatment antibody concentration ≥ the cut-off value; For a seropositive patient: a post-treatment antibody concentration ≥ twice the pre-treatment antibody concentration.

Tumor response was assessed by the Response Evaluation Criteria In Solid Tumors (RECIST), where stable disease for target lesions refers to neither enough shrinkage to qualify for complete response nor sufficient increase to qualify for progressive disease taking as references the smallest sum longest diameter (LD) since the treatment started. For non-targeted lesions it refers to persistence of one or more non-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these.

Tumor response was assessed by the RECIST criteria, where SD for target lesions refers to neither enough shrinkage to qualify for CR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter (LD) since the treatment started. For non-targeted lesions it refers to persistence of one or more nom-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these. Mixed response is defined as at least 30% decrease in the LD occurring in at least one target lesion recorded and measured at baseline. Such response occurring in otherwise SD or PD status of the LD of target lesions were classified as "SD with target lesion regression" or "PD with target lesion regression", respectively. New lesion(s) in otherwise PR status of the LD of target lesions were "PR with new lesion".

Analysis of immunogenicity for anti-PD antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.

Analysis of immunogenicity for anti-CpG antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.

Time to treatment failure (TTF) was defined as the time from first administration of study product until the date of the last administration of the product, irrespective of the reason for study treatment discontinuation. Progression-free survival (PFS) was defined as the time from first adminsitration of study product until the date of either disease progression or death (for whatever reason), whichever comes first. Overall survival (OS) was defined as the time from first administration of study product until death.

This analysis was not performed following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG/anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.

GlaxoSmithKline

GSK2302025A Cohort 1

GSK2302025A Cohort 2

GSK2302025A Cohort 3

GSK2302025A Cohort 4

Total

Age, Continuous

Sex: Female, Male

Geographic Ancestry

Race/Ethnicity, Customized

As a consequence of the decision to stop the study, not all data are available for a full final analysis as originally planned. Analyses are merely descriptive and the results are presented as an abridged study report.

GSK Response Center

Patients with DLT

Patients with related DLT

Patients with severe DLT

Brain oedema

Microalbuminuria

Proteinuria

The analysis was performed on Phase 1 subjects from the Total treated population, which included all enrolled patients who have received at least one study dose injection.

Number of Patients With Dose-limiting Toxicity (Phase I)

The analysis was performed on Phase 1 subjects with available results at Week 8, from the Total treated population, which included all enrolled patients who have received at least one study dose injection.

Percentage of Patients With Anti-PReferentially Expressed Antigen of MElanoma (Anti-PRAME) Humoral Immune Response (Phase I)

Patients with CR

Patients with PR

The analysis was performed on the Total treated population, which included all enrolled patients who have received at least one study dose injection.

Number of Patients With Best Overall Response to Study Treatment (Phase II)

Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

Number of Patients With Any Unsolicited Adverse Events (AEs), by Maximum Grading

Number of Patients With Serious Adverse Events (SAEs), by Maximum Grading

[APTTP], G0-GUnknown

[APTTP], G1-GUnknown

[APTTP], G2-GUnknown

[APTTP], G3-GUnknown

[APTTP], G4-GUnknown

[APTTP], GUknown-GUnknown

[APTTP], G0-G0

[APTTP], G1-G0

[APTTP], G2-G0

[APTTP], G3-G0

[APTTP], G4-G0

[APTTP], GUnknown-G0

[APTTP], G0-G1

[APTTP], G1-G1

[APTTP], G2-G1

[APTTP], G3-G1

[APTTP], G4-G1

[APTTP], GUnknown-G1

[APTTP], G0-G2

[APTTP], G1-G2

[APTTP], G2-G2

[APTTP], G3-G2

[APTTP], G4-G2

[APTTP], GUknown-G2

Number of Patients With Laboratory Abnormalities Versus Baseline, by Maximum Grading

[ALT/I], G0-G0

[ALT/I], G1-G0

[ALT/I], G2-G0

[ALT/I], G3-G0

[ALT/I], G4-G0

[ALT/I], GUknown-G0

[ALT/I], G0-G1

[ALT/I], G1-G1

[ALT/I], G2-G1

[ALT/I], G3-G1

[ALT/I], G4-G1

[ALT/I], GUknown-G1

[APH/I], G0-G0

[APH/I], G1-G0

[APH/I], G2-G0

[APH/I], G3-G0

[APH/I], G4-G0

[APH/I], GUknown-G0

[APH/I], G0-G1

[APH/I], G1-G1

[APH/I], G2-G1

[APH/I], G3-G1

[APH/I], G4-G1

[APH/I], GUknokwn-G1

[APH/I], G0-G2

[APH/I], G1-G2

[APH/I], G2-G2

[APH/I], G3-G2

[APH/I], G4-G2

[APH/I], GUknown-G2

Number of Patients With Laboratory Abnormal Results Versus Baseline, by Maximum Grading

[AN], G0-G0

[AN], G1-G0

[AN], G2-G0

[AN], G3-G0

[AN], G4-G0

[AN], GUknown-G0

[AN], G0-G1

[AN], G1-G1

[AN], G2-G1

[AN], G3-G1

[AN], G4-G1

[AN], GUnknown-G1

[AST/I], G0-G0

[AST/I], G1-G0

[AST/I], G2-G0

[AST/I], G3-G0

[AST/I], G4-G0

[AST/I], GUnknown-G0

[AST/I], G0-G1

[AST/I], G1-G1

[AST/I], G2-G1

[AST/I], G3-G1

[AST/I], G4-G1

[AST/I], GUnknown-G1

[BB/I], G0-G0

[BB/I], G1-G0

[BB/I], G2-G0

[BB/I], G3-G0

[BB/I], G4-G0

[BB/I], GUnknown-G0

[BB/I], G0-G1

[BB/I], G1-G1

[BB/I], G2-G1

[BB/I], G3-G1

[BB/I], G4-G1

[BB/I], GUnknown-G1

Number of Patients With Hematological and Biochemical Abnormalities Versus Baseline, by Maximum Grading

[CRE/I], G0-G0

[CRE/I], G1-G0

[CRE/I], G2-G0

[CRE/I], G3-G0

[CRE/I], G4-G0

[CRE/I], GUnknown-G0

[CRE/I], G0-G1

[CRE/I], G1-G1

[CRE/I], G2-G1

[CRE/I], G3-G1

[CRE/I], G4-G1

[CRE/I], GUnknown-G1

[CRE/I], G0-G2

[CRE/I], G1-G2

[CRE/I], G2-G2

[CRE/I], G3-G2

[CRE/I], G4-G2

[CRE/I], GUknown-G2

[GGT/I], G0-G0

[GGT/I], G1-G0

[GGT/I], G2-G0

[GGT/I], G3-G0

[GGT/I], G4-G0

[GGT/I], GUnknown-G0

Number of Patients With Laboratory Hematological and Biochemical Abnormalities Versus Baseline, by Maximum Grading

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer	NCT01149343	Melanoma	Immunotherapeut...	18 Years -	GlaxoSmithKline
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma	NCT02743611	Acute Myeloid L... Myelodysplastic... Uveal Melanoma	BPX-701 Rimiducid	18 Years -	Bellicum Pharmaceuticals
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer	NCT01149343	Melanoma	Immunotherapeut...	18 Years -	GlaxoSmithKline
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery	NCT01159964	Lung Cancer, No...	Immunotherapeut...	18 Years -	GlaxoSmithKline
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors	NCT05812027	Head and Neck C... Cervical Cancer Non Small Cell ... Melanoma Ovarian Cancer HPV16 Related C...	Tumor and HLA P...	18 Years -	TScan Therapeutics, Inc.
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors	NCT05812027	Head and Neck C... Cervical Cancer Non Small Cell ... Melanoma Ovarian Cancer HPV16 Related C...	Tumor and HLA P...	18 Years -	TScan Therapeutics, Inc.

Spots Global Cancer Trial Database for prame

Every month we try and update this database with for prame cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for prame

Every month we try and update this database with for prame cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for prame cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.